SuperC Long Term Plays

[SuperC]

FROI .012 <SpotLight Pick> A fully reporting OTCQB Company.

Fero Industries Inc OTCQB .0119
Chart showing a nice double bottom and a 'loose' triple bottom with the candle 'wick' touch late June...
http://stockcharts.com/c-sc/sc?s=FROI&p=D&yr=0&mn=6&dy=0&i=p85613630009&a=240928153&r=7089

FERO Industries; who are they and what do they have in regards to a Type 2 Diabetic Drug?

GlaxoSmithKline; who are they and what do they have in regards to a Type 2 Diabetic Drug?

Fero Industries Owns: Sucanon

GlaxoSmithKline own: Avandia

One of the first and most important reads too this entire story: http://www.thestreet.com/story/10810844/fero-industries-comments-on-recent-fda-advisory-panel-recommendation-on-avandia174.html

As competitors in a small world of "insulin sensitizer’s", excerpt taken from article>> <Sucanon ® is one of only three approved drugs in what is a $5.6 billion dollar market>], and of course the main product being widely distributed for a number of years is Avandia.

Avandia though is in trouble from a number of standpoints referred in this article: http://www.bloomberg.com/news/2011-07-26/glaxo-revenue-declines-for-third-quarter-on-lower-avandia-valtrex-demand.html
"The company’s revenue decline, the smallest in three quarters, also was in line with analyst estimates, with lower sales of the Avandia diabetes drug".

The current road even though Avandia is allowed too stay on the market is not a good one: http://www.google.com/search?q=avandia+complaints&ie=utf-8&oe=utf-8&aq=t&rls

In August, 2007, the FDA announced the manufacturers of Avandia and Actos have agreed to add a stronger warning on the risk of heart failure

So, along comes a product purchased by FERO Industries: On June 29, 2010, Fero Industries, Inc., a Colorado corporation, (the “Company”) closed that certain Asset Acquisition Agreement (“Agreement”), by and between the Company and Gvest, Inc., an Ontario, Canada corporation, (“Gvest”) dated May 23, 2010. Pursuant to the terms and conditions of the Agreement, the Company acquired certain assets of Gvest directly related to the manufacturing, sale and distribution of that certain product known as Sucanon®, which is a treatment for Type II Diabetes. The acquired assets include all of the intellectual property rights, training, and “know how” to manufacture and produce Sucanon®; sources and suppliers of Sucanon® ingredients and mixing equipment; certain associated trademarks, patents; and a domain name for Sucanon health. Additionally, the Company acquired ownership rights in various corporations; collectively giving the Company the exclusive world-wide rights to manufacture, sell and distribute Sucanon®, in exchange for an aggregate of $250,000, paid to Gvest.
http://www.faqs.org/sec-filings/100701/FERO-INDUSTRIES-INC_8-K/#ixzz1U0uwafPT

Sucanon™
Analysis Overview: http://www.google.com/search?q=Sucanon+type+II+diabetes+analysis&ie=utf-8&oe=utf-8&aq=t&rls=

For those who understand changes in glucose abnormalities http://www.sucanonhealth.com/section.asp?catid=756 early studies.
__________________________________________________________________________________

Fero Industries Inc OTCQB .0119
Chart showing a nice double bottom and a 'loose' triple bottom with the candle 'wick' touch late June...
http://stockcharts.com/c-sc/sc?s=FROI&p=D&yr=0&mn=6&dy=0&i=p85613630009&a=240928153&r=7089

Was this ready in December of 2010? Not Quite!
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57873677
____________________________________________________________________________________
This is about a product called Sucanon® the mainstay for FERO Industries. Sucanon is an herbal remedy, not a drug. Merck's Mexican subsidiary Merck SA de CV (Merck Mexico) has widened its distributing network for Fero Industries' over the counter (OTC) drug Sucanon by increasing outlets and pharmacy chains from 900 to over 2,500 in Mexico. Walmart and others are included.
Everyone familiar with the name: http://www.merck.com/index.html

From all that I have read, I find this particular stock; at this particular time an excellent opportunity for a Long-Term-Play, and especially at these prices given all areas of news coverage, i.e. Product & Competition.

Contact Info

254-16 Midlake Boulevard SE
Calgary, ALB T2X 2X7
Canada
Phone: [phone]

http://www.feroindustries.com

Mr. Luis Lopez - Managing Director Pharmaroth Latin America S.A. de C.V., Director. Since 2005, Mr. Lopez has been Managing Director of Pharmaroth Latin America S.A. de C.V., the 98% owned Mexican operating subsidiary of the Company. Luis has been involved with Sucanon® since its earliest stages of development. Mr. Lopez's intimate knowledge and experience with Sucanon® in Mexico make him uniquely qualified as a member of the Company's board of directors and global management team.

Kyle Schlosser CEO, President

Leigh-Ann Squire CFO, Treasurer, Secretary

Authorized Shares 500mil
Outstanding Shares 149mil
Float approx. 141mil [still working on final #'s]

Recent historical volume/pps change: http://ih.advfn.com/p.php?pid=historical&cb=1264248899&symbol=froi

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=7939174

http://www.otcmarkets.com/stock/FROI/financials

http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=froi

News Item Headers:

07/27/20116:00AM
Fero Industries Increases Sucanon® Promotion in Mexico with Physician Distributed Sample PackagesUSOTC:FROIFero Industries New (QB)

07/13/201110:11AM
Fero Industries Expands Sucanon® Distribution in MexicoUSOTC:FROIFero Industries New (QB)

06/23/20117:32AM
Fero Industries Contracts PNP Pharmaceuticals for Exclusive Global Sucanon® ProductionUSOTC:FROIFero Industries New (QB)

06/01/20117:49AM
Fero Industries Successfully Completes Sucanon® Type-2 Diabetes Human Clinical Trials in the Middle EastUSOTC:FROIFero Industries New (QB)

05/19/20116:30AM
Fero Industries Announces Third Quarter Results and Initial Revenue From Sucanon(R) Sales in MexicoUSOTC:FROIFero Industries, Inc.

05/16/20115:08PMForm (10-Q)
Quarterly Report USOTC:FROIFero Industries

04/12/20118:33AM
Fero Industries Appoints Lopez as Chief Operating OfficerUSOTC:FROIFero Industries, Inc.

03/31/20119:25AM
Fero Industries Makes Third Commercial Shipment of Sucanon(R) to Merck S.A.USOTC:FROIFero Industries, Inc.

03/16/20118:30AM
Fero Industries Announces Commercial Launch of Sucanon(R) in MexicoUSOTC:FROIFero Industries, Inc.

03/09/20114:52PM
Amended Quarterly Report (10-Q/A)USOTC:FROIFero Industries

02/16/20119:23AM
Sucanon(R) Type-2 Diabetes Clinical Trials Reach Final Stage in Middle EastUSOTC:FROIFero Industries, Inc.

Sucanon is one of only several drugs in the world, belonging to a class of diabetic medications called insulin sensitizers. Insulin sensitizers lower blood sugar by increasing the muscle, fat and liver's sensitivity to insulin. Insulin sensitizers are blood sugar normalizing or euglycemic drugs that help return the blood sugar to the normal range without the risk of low blood sugars.

So, are there proven side effect with Sucanon?
One of many studies I’ve found, all seem to be very positive.

Accompanying is a review of insulin sensitizer drugs appearing in the May – June, 2007 issue of Diabetes Hoy, V. VIII no. 3, pp. 1834-1835. Diabetes Hoy (“Diabetes Today”) is the official scientific-medical publication of the Mexican Diabetes Federation and is directed to an audience of doctors and health professionals. The review, by Dr. Roberto Gonzales, Medical Director of the Center Specialized in Diabetes (CAED), Mexico City, notes issues with and contraindications for use of the use of insulin-sensitizer drugs from the glitazone family including Avandia and Actos, as well as limitations on the use of widely used biguanide and sulfonylurea drugs. Dr. Gonzales’ overview concludes with a section on “a new sensitizer”, Sucanon, which Dr. Gonzales describes as having “great effectiveness and low risk”, which gives Sucanon “great potential”. A translation of Dr. Gonzales’ overview of Sucanon follows:
Recently a new insulin sensitizer has been launched onto the market. This product, Sucanon, has its base and pharmacological origin in the dry extract of root of trichosanthis (trichosanthis kirilowii) and manitolatodimolybdate complex. The product, which is of natural origin and has been directed towards the treatment of hyperglycemia, with its mechanism of action being based on potentiating the utilization of insulin in the cells (principally muscle cells), is considered to fall in the category of insulin sensitizers.

The use of [this] new product of herbal origin (Sucanon) in patients with Type II Diabetes who are also obese, as well as improving the utilization of glucose by the organism, reduces weight gain, which in turn facilitates improved control in the patient with diabetes. In the studies which have been carried out, Sucanon, in contrast to the class of drugs known as thiazolidinediones, did not present any liver toxicity and in contrast to the biguanide drugs such as metformin, did not require restrictions when used by patients with renal insufficiency (often a complication of Type II Diabetes), which is a frequent side effect in the treatment of Type II diabetic patients, particularly those are obese. -- From article entitled “Sensibilizadoras de insulina” by Dr. Robert Cepeda Gonzales, published in Diabetes Hoy (Diabetes Today), May-June 2007, vol. 8, number 3, pp.1834-1835

Who's manufacturing Sucanon? http://www.pnppharmaceuticals.com
http://ih.advfn.com/p.php?pid=nmona&article=48177941

Past articles in 2010:
http://www.investmentvibes.com/?p=931

March 2011:
http://thestockmarketwatch.com/newsletters/2011/03/28/froi-could-be-one-of-our-best-picks-ever

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=65138369&txt2find=froi


Fero Industries, Inc. (OTCQB: FROI) (OTCBB: FROI) (the "Company") is pleased to announce the release of its third quarter financial statements for the period ended March 31, 2011. The third quarter financial statements highlight the successful commercial launch of Sucanon® in Mexico and initial revenue from Sucanon® sales made by Merck S.A. de C.V.
"This past quarter was certainly the most exciting period in our Company's history, and I am proud to say that through the hard work and determination of our entire team, we were able to reach many important new milestones," said Mr. Luis Lopez, Chief Operating Officer of Fero Industries.
"None of these achievements was more significant than the successful commercial launch of Sucanon® in Mexico and receiving the first revenue from its sale. These results, however, represent only a small fraction of the overall market potential for Sucanon® in Mexico. We expect both revenues and margins to grow dramatically as new patients adopt Sucanon® into their daily type-2 diabetes management routine, and Sucanon distribution expands beyond Mexico to include countries in South America, Asia, and the Middle East."
Given the latest news, accounts, FROI at .04 in March well before the last 10q included, I believe this one warrants further DD and an excellent buy at this level.

http://stockcharts.com/h-sc/ui?s=FROI&p=D&yr=0&mn=3&dy=0&id=p81601781816

http://investorshub.advfn.com/boards/board.aspx?board_id=16240

52-Wk Range .0119 - 0.073
Current .0119

Please continue to read each link, check all data for both Suncanon & Avandia.

Read recent news and related studies too include countries with ongoing trials.

This product from all the DD I’ve discovered could be a real game changer. Others in the past have know it, posted on different stock sites, http://thestockmarketwatch.com/newsletters/2011/03/28/froi-could-be-one-of-our-best-picks-ever but only until now I believe this one is ready too head north!
http://www.google.com/search?q=FERO+FROI+stock+pick&hl=en&client=

Is this a new play or a play now ready?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57873677

I just happen to believe this one is ready too include the 'green-signals' EOD Aug 3rd 2011 at .0119

DD_YOU!!

Trade Well but do not trade this one Often!

SuperC